Trials / Not Yet Recruiting
Not Yet RecruitingNCT07322159
IASO206 in Patients With Relapsed/Refractory Multiple Myeloma
An Exploratory Study of Safety and Efficacy of IASO206 in Patients With Relapsed/Refractory Multiple Myeloma
- Status
- Not Yet Recruiting
- Phase
- EARLY_Phase 1
- Study type
- Interventional
- Enrollment
- 12 (estimated)
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study is an open-label, single-arm early exploratory clinical study, aiming to evaluate the safety, tolerability and preliminary efficacy of IASO206 Injection(In Vivo CAR-T) in Patients with Relapsed/Refractory Multiple Myeloma
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | IASO206 injection | The third-generation self-inactivating lentiviral vector that carries a BCMA-targeted CAR. |
Timeline
- Start date
- 2026-01-15
- Primary completion
- 2026-10-15
- Completion
- 2028-10-15
- First posted
- 2026-01-07
- Last updated
- 2026-01-07
Source: ClinicalTrials.gov record NCT07322159. Inclusion in this directory is not an endorsement.